一、获奖

（1）南京药学会2018年度科学技术一等奖，R3

（2）江苏省2018年度江苏省医学新技术引进二等奖，R3

二、代表性论著

[1] Zhang, X.*;Cai, X.; Zheng, X.*, Gut microbiome-oriented therapy for metabolic diseases:challenges and opportunities towards clinical translation. TrendsPharmacol Sci 2021, 42(12):984-987. (IF 14.819 )

[2] Zhang, X.*; Zhao, Y.;Shao, H.; Zheng, X.*, Metabolic and endocrinal effects ofN-desmethyl-olanzapine in mice with obesity: Implication forolanzapine-associated metabolic changes. Psychoneuroendocrinology 2019,108, 163-171. (IF 4.905)

[3] Zhang, X.*; Zhao, Y.; Liu,Y.; Yuan, Y.; Shao, H.; Zheng, X.*, Regulation of obesity-associated metabolicdisturbance by the antipsychotic drug olanzapine: Role of theautophagy-lysosome pathway. BiochemPharmacol 2018, 158, 114-125. (IF 5.858)

[4] Zhang, X.*; Zhao, Y.;Chen, S.; Shao, H.*, Anti-diabetic drugs and sarcopenia: emerging linksmechanistic insights, and clinical implications. J Cachexia Sarcopeni2021, 12(6):1368-1379. (IF 12.910 )

[5] Zhang, X.*; Shao, H.;Zheng, X.*, Amino acids at the intersection of nutrition and insulinsensitivity. Drug Discov Today 2019, 24 (4), 1038-1043. (IF 7.851)

[6] Zhang, X.; Liu, Y.; Shao,H.; Zheng, X.*, Obesity Paradox in Lung Cancer Prognosis: Evolving BiologicalInsights and Clinical Implications. JThorac Oncol 2017, 12 (10), 1478-1488. (IF 15.609)

[7] Yang, J.#; Zhang,X.#; Yuan, P.; Xu, Y.; Grutzendler, J.; Shao, Y.; Moore, A.*;Ran, C.*, Oxalate-curcumin-based probe for micro- and macroimaging of reactiveoxygen species in Alzheimer's disease. ProcNatl Acad Sci U S A 2017, 114 (47), 12384-12389. (IF 9.412)

[8] Yang, J.#; Zhang,X.#; Zhu, Y.; Lenczowski, E.; Tian, Y.; Zhang, C.;  Hardt, M.; Qiao, C.;  Tanzi, R. E.;  Moore, A.; Ye, H.; Ran, C.*, The double-edged role of copper in the fate of amyloidbeta in the presence of anti-oxidants. ChemSci 2017, 8 (9), 6155-6164. (IF 9.825)

[9] Zhang, X.; Guo, F.; Shao,H.*; Zheng, X.*, Clinical translation of polymyxin-based combination therapy:Facts, challenges and future opportunities. J Infect 2017, 74 (2), 118-130. (IF 6.072)

[10] Zhang, X.*; Zheng, X.*;Yuan, Y., Treatment of insulin resistance: straight from the gut. Drug Discov Today 2016,21 (8), 1284-90. (IF 7.851)

[11] Zhang, X.#;Tian, Y.#; Zhang, C.; Tian, X.; Ross, A. W.; Moir, R. D.; Sun, H.;Tanzi, R. E.;  Moore, A.*; Ran, C.*,Near-infrared fluorescence molecular imaging of amyloid beta species andmonitoring therapy in animal models of Alzheimer's disease. Proc Natl Acad Sci U S A 2015,112 (31), 9734-9. (IF 9.412)

[12] Zhang, X., Tian, Y., Yuan,P., Li, Y., Yaseen, M. A., Grutzendler, J., Moore, A.*, Ran, C.*, Abifunctional curcumin analogue for two-photon imaging and inhibitingcrosslinking of amyloid beta in Alzheimer's disease. Chem Commun (Camb) 2014, 50 (78), 11550-3. (IF 6.222)

[13] Zhang, X., Tian, Y., Li,Z., Tian, X., Sun, H., Liu, H., Moore, A.*, Ran, C.*, Design and synthesis ofcurcumin analogues for in vivo fluorescence imaging and inhibitingcopper-induced cross-linking of amyloid beta species in Alzheimer's disease.J Am Chem Soc 2013, 135 (44), 16397-409. (IF 15.419)